Education
About Us
Working with TipRanks
Follow Us
Xeris Pharmaceuticals (XERS)
NASDAQ:XERS
XERS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.69 - $6.07
Previous CloseN/A
Volume530.95K
Average Volume (3M)3.76M
Market Cap
$631.15M
Enterprise Value$705.25M
Total Cash (Recent Filing)-$32.27M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.25
Next Earnings
May 07, 2025EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding153,940,140
10 Day Avg. Volume2,750,397
30 Day Avg. Volume3,755,286
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.40
Price to Cash Flow (P/CF)113.20
P/FCF Ratio127.40
Enterprise Value/Market Cap1.12
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit4.24
Enterprise Value/Ebitda-50.40
Forecast
1Y Price Target
$6.10Price Target Upside42.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Xeris Pharmaceuticals News
PremiumCompany Announcements
Xeris Pharmaceuticals Announces Board Changes with New Appointment
PremiumCompany Announcements
Xeris Biopharma’s Earnings Call Highlights Growth and Optimism
---
Bulls Say, Bears Say
Bulls Say
Cash FlowXeris generated positive cash flow in 4Q24 and expects to end FY24 with ~$71M in cash and cash equivalents, within their prior cash guidance.
EarningsXeris' record 4Q24 performance marks a transformative inflection point with accelerating commercial momentum and first-time positive adjusted EBITDA, which is a strong positive setup going into 2025.
Product PerformanceBoth of Xeris’ growth drivers, Recorlev and Gvoke, beat estimates with particularly impressive upside from Recorlev.
Revenue GrowthXeris reported 4Q24 financials with total net product revenues of $57.0M, representing ~34% Y/Y growth and marking the 13th consecutive quarter of >20% growth.
Bears Say
Market ValuationDespite recent stock strength, the stock is still viewed as undervalued.
PartnershipsAmgen terminated their XeriJect license agreement with Xeris, which might weigh on the stock incrementally.
---
Ownership Overview
6.12% Insiders
8.20% Mutual Funds
0.12% Other Institutional Investors
73.83% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
XERS FAQ
What was Xeris Pharmaceuticals’s price range in the past 12 months?
Xeris Pharmaceuticals lowest stock price was $1.69 and its highest was $6.07 in the past 12 months.
What is Xeris Pharmaceuticals’s market cap?
Xeris Pharmaceuticals’s market cap is $631.15M.
When is Xeris Pharmaceuticals’s upcoming earnings report date?
Xeris Pharmaceuticals’s upcoming earnings report date is May 07, 2025 which is in 12 days.
How were Xeris Pharmaceuticals’s earnings last quarter?
Xeris Pharmaceuticals released its earnings results on Mar 06, 2025. The company reported -$0.03 earnings per share for the quarter, beating the consensus estimate of -$0.056 by $0.026.
Is Xeris Pharmaceuticals overvalued?
According to Wall Street analysts Xeris Pharmaceuticals’s price is currently Undervalued.
Does Xeris Pharmaceuticals pay dividends?
Xeris Pharmaceuticals does not currently pay dividends.
What is Xeris Pharmaceuticals’s EPS estimate?
Xeris Pharmaceuticals’s EPS estimate is -0.05.
How many shares outstanding does Xeris Pharmaceuticals have?
Xeris Pharmaceuticals has 153,940,140 shares outstanding.
What happened to Xeris Pharmaceuticals’s price movement after its last earnings report?
Xeris Pharmaceuticals reported an EPS of -$0.03 in its last earnings report, beating expectations of -$0.056. Following the earnings report the stock price went up 9.549%.
Which hedge fund is a major shareholder of Xeris Pharmaceuticals?
Currently, no hedge funds are holding shares in XERS
---
Xeris Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.10 (42.52% Upside)
$6.10 (42.52% Upside)
Blogger Sentiment
Bullish
XERS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 598.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $217.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.1%
Last 30 Days ▼ 0.6%
Last 30 Days ▼ 0.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
132.02%
12-Months-Change
Fundamentals
Return on Equity
222.83%
Trailing 12-Months
Asset Growth
-3.42%
Trailing 12-Months
Company Description
Xeris Pharmaceuticals
Xeris Pharmaceuticals, Inc. is a specialty pharmaceutical company that focuses on developing and commercializing innovative therapies for the treatment of endocrine and metabolic diseases. The company is known for its proprietary technology platforms, including the XeriSol and XeriJect formulation technologies, which enhance the delivery and stability of injectable therapeutics. Xeris Pharmaceuticals primarily operates in the biopharmaceutical sector, offering solutions that address critical unmet medical needs for patients and healthcare providers.
---
XERS Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Xeris Biopharma's earnings call highlighted significant revenue growth and positive developments in their product portfolio, particularly with Recorlev and Gvoke. The company also achieved positive adjusted EBITDA for the first time. Despite the decline in Keveyis revenue and anticipated pressure on its reimbursement, the company is optimistic about its growth prospects for 2025.Read More>---
XERS Stock 12 Month Forecast
Average Price Target
$6.10
▲(42.52% Upside)
Technical Analysis
Xencor
―
Zymeworks
―
Nurix Therapeutics
―
Praxis Precision Medicines
―
AbCellera Biologics
―
Best Analysts Covering XERS
1 Year
1 Year Success Rate
15/23 ratings generated profit
1 Year Average Return
+28.38%
reiterated a buy rating 2 months ago
Copying Roanna Ruiz's trades and holding each position for 1 Year would result in 65.22% of your transactions generating a profit, with an average return of +28.38% per trade.
---